Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Employer Options For Retiree Health Plans Outlined In Proposed Medicare Drug Rule

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS is declining to predict whether the four retiree health coverage options available to employers and outlined in a Medicare proposed rule issued July 26 will be sufficient to stem the tide of employer dropouts

You may also be interested in...



Employer Drug Coverage Will Shift To Part D, Stakeholders Say

Companies will accept the government subsidy for retirees’ drug coverage initially, but will move former workers to the Medicare drug benefit in later years, executives from Kaiser Foundation Health Plans and the Employers Coalition on Medicare predict.

Employer Drug Coverage Will Shift To Part D, Stakeholders Say

Companies will accept the government subsidy for retirees’ drug coverage initially, but will move former workers to the Medicare drug benefit in later years, executives from Kaiser Foundation Health Plans and the Employers Coalition on Medicare predict.

Medicare Wrap-Around Coverage May Be Best Option For Employers – CMS

Employers have the option of continuing retiree coverage and receiving a federal subsidy or providing enhanced coverage by wrapping around Medicare drug plans. CMS estimates that savings available to employers through wrap-around options would amount to an additional $300 per beneficiary over the direct federal subsidy option.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel